<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Currently, no prospective data exists to support a "stop-and-go" modified FOLFOX6 regimen with bevacizumab in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) patients </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to evaluate the efficacy and safety of this regimen in first-line mCRC patients </plain></SENT>
<SENT sid="2" pm="."><plain>Eligible patients (age ≥20 years) had previously untreated mCRC; Eastern Cooperative <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group performance status of 0-2; and adequate hematologic, hepatic, and renal function </plain></SENT>
<SENT sid="3" pm="."><plain>The modified FOLFOX6 regimen and bevacizumab (5 mg/kg) was administered intravenously every 2 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>After 8 cycles, patients received maintenance therapy with simplified LV5FU2 and bevacizumab until completion of 8 cycles or disease progression </plain></SENT>
<SENT sid="5" pm="."><plain>After maintenance therapy, patients received another 8 cycles of modified FOLFOX6 with bevacizumab until completion of 8 cycles or disease progression </plain></SENT>
<SENT sid="6" pm="."><plain>We recruited 50 patients between August 2007 and January 2009 </plain></SENT>
<SENT sid="7" pm="."><plain>The overall response rate was 48% (80% confidence interval [CI]; 38.2-58) with outcomes as follows: complete response, n = 1; partial response, n = 23; stable disease, n = 21; progression, n = 1; and not evaluated, n = 4 </plain></SENT>
<SENT sid="8" pm="."><plain>Median time to treatment failure was 7.7 months (80% CI: 6.2-8.0), and median progression-free survival was 12.8 months (80% CI: 10.8-14) </plain></SENT>
<SENT sid="9" pm="."><plain>Grade 3/4 toxicities included <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (40%), <z:hpo ids='HP_0002018'>nausea</z:hpo> (4%), <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (14%), <z:mp ids='MP_0005048'>thrombosis</z:mp> (4%), and <z:hpo ids='HP_0000822'>hypertension</z:hpo> (4%) et al </plain></SENT>
<SENT sid="10" pm="."><plain>Grade 1, 2, or 3 <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> was reported in 38%, 40%, and 10% of patients, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>The stop-and-go modified FOLFOX6 and bevacizumab regimen is effective and well tolerated as first-line chemotherapy for mCRC patients </plain></SENT>
</text></document>